

OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person * <u>Hippel James</u> _____ (Last) (First) (Middle) <u>614 MCKINLEY PLACE NE</u> _____ (Street) <u>MINNEAPOLIS MN 55413</u> _____ (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>BIO-TECHNE Corp [ TECH ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner Officer (give title below) _____ Other (specify below) <p style="text-align: center;"><b>CFO</b></p>
	3. Date of Earliest Transaction (Month/Day/Year) <u>08/02/2024</u>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	08/02/2024		M		53,000	A	\$31.26	136,002	D	
Common Stock	08/02/2024		F		36,076	D	\$82.35	99,926	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Options (Right to Buy)	\$31.26	08/02/2024		M			53,000	(1)	08/09/2024	Common Stock	53,000	\$0	53,867	D	
Stock Options (Right to Buy)	\$44.33							(1)	08/08/2025	Common Stock	168,620		168,620	D	
Stock Options (Right to Buy)	\$47.6							(1)	08/07/2026	Common Stock	186,068		186,068	D	
Stock Options (Right to Buy)	\$66.97							(1)	08/05/2027	Common Stock	167,328		167,328	D	
Stock Options (Right to Buy)	\$120.46							(2)	08/06/2028	Common Stock	40,536		40,536	D	
Restricted Stock Units	(3)							(4)	(4)	Common Stock	10,912		10,912	D	
Performance Stock Options (Right to Buy)	\$94.52							(4)	08/15/2029	Common Stock	33,916		33,916	D	
Stock Options (Right to Buy)	\$94.52							(5)	08/15/2029	Common Stock	45,220		45,220	D	
Restricted Stock Units	(3)							(6)	(6)	Common Stock	13,865		13,865	D	
Performance Stock Options (Right to Buy)	\$84.61							(6)	08/15/2030	Common Stock	37,314		37,314	D	
Stock Options (Right to Buy)	\$84.61							(7)	08/15/2030	Common Stock	45,923		45,923	D	
Restricted Stock Units	(3)							(8)	(8)	Common Stock	26,318		26,318	D	

**Explanation of Responses:**

- Fully exercisable.
- Options to purchase 10,134 shares vest on each of 8/6/2022, 8/6/2023, 8/6/2024 and 8/6/2025.
- Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock.

4. Vests in full or in part on 8/15/2025 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
5. Options to purchase 11,305 shares vest on each of 8/15/2023, 8/15/2024, 8/15/2025 and 8/15/2026.
6. Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
7. Options to purchase 11,481 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027, and options to purchase 11,480 shares vest on 8/15/2026.
8. 13,159 restricted stock units vest on each of 11/1/2024 and 11/1/2025.

/s/ Andrew Nick as Attorney-in-  
Fact for James Hippel pursuant to 08/06/2024  
Power of Attorney previously filed

\*\* Signature of Reporting Person                      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**